Lymphoma Clinical Trials in San Diego

Showing 161-180 of 204 trials

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

NCT00726934

The purpose of this study is to determine if FDA approved food safety guidelines are equivalent to a low bacterial diet (the neutropenic diet) with respect to the acquisition of infections during neutropenia in a sample of pediatric cancer patients.

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaNon-Hodgkins Lymphoma+2 more

Indiana University149 participantsStarted Sep 2007

San Diego, California, United States • Indianapolis, Indiana, United States • Brooklyn, New York, United States +3 more locations

COMPLETEDPHASE2< 1 mile

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

NCT00553501

RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving epratuzumab and rituximab together may be more effective in treating follicular non-Hodgkin lymphoma. PURPOSE: This phase II trial is studying how well giving epratuzumab together with rituximab works in treating patients with previously untreated follicular non-Hodgkin lymphoma.

Lymphoma

Alliance for Clinical Trials in Oncology60 participantsStarted Mar 2008

San Diego, California, United States • San Francisco, California, United States • Middletown, Connecticut, United States +40 more locations

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Lymphoma Trials in Other Cities

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Other Conditions in San Diego